SCHEMBL22290741

SCHEMBL22290741

CC(C)(C)OC(=O)c1ccn(C(C)(C)C(=O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
SLC7A5 Q01650 1/20 0.37
ALDH1A1 P00352 3/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
SRD5A1 P18405 1/20 0.34
ELANE P08246 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22290652 0.84 DGAT1 (0.38) CA12CA1CA2CA9CA14
SCHEMBL22290641 0.81 CA12 (0.40) CA12CA1CA2CA9CA14
SCHEMBL22290296 0.81 CA12 (0.37) CA12CA1CA2CA9CA14
SCHEMBL22290530 0.78 CA12 (0.35) CA12CA1CA2CA9CA14
SCHEMBL27556525 0.77 CA12 (0.45) CA12CA1CA2CA9CA14
SCHEMBL15180434 0.77 CA12 (0.41) CA12CA1CA2CA9CA14
SCHEMBL28509626 0.74 AKR1B1 (0.55) CA12CA1CA2CA9CA14
SCHEMBL24049473 0.73 CA12 (0.39) CA12CA1CA2CA9CA14
SCHEMBL34469716 0.73 CA12 (0.39) CA12CA1CA2CA9CA14
SCHEMBL19895794 0.72 TDP1 (0.62) CA12CA1CA2CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 CN disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CA12 4343/4885CA1 4780/4885CA2 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.